Web Results

en.wikipedia.org/wiki/GlaxoSmithKline

In 1959 the Wellcome Foundation bought Cooper, McDougall & Robertson Inc to become more active in animal health. Glaxo and Wellcome merged in 1995 to form Glaxo Wellcome plc. Glaxo Wellcome restructured its R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D ...

www.gsk.com

The homepage of the GSK global corporate website.

www.gsk.com/en-gb/about-us/our-history

It began when Plough Court Pharmacy was established in 1715. Discover GSK's journey through the centuries that led to the organisation we know today.

www.wsj.com/articles/SB948069657140115932

Jan 17, 2000 ... In early November, SmithKline Beecham PLC's Chief Executive Jan Leschly offered Glaxo Wellcome PLC Chairman Sir Richard Sykes a lift on SmithKline's corporate jet from London to a blue-ribbon industry conference in Switzerland. It was a surprising invitation -- relations between the two executives ...

www.nytimes.com/2000/01/17/business/glaxo-and-smithkline-agree-to-form-largest-drugmaker.html

Jan 17, 2000 ... The British drugmaker Glaxo Wellcome agreed tonight to buy one of its chief rivals, SmithKline Beecham, for about $76 billion, creating the world's largest pharmaceutical company, executives close to the talks said. The combined company, to be called Glaxo SmithKline, would be a powerhouse in Europe ...

www.nytimes.com/1995/01/24/business/company-news-glaxo-offers-14-billion-for-wellcome.html

Jan 24, 1995 ... Taking the steady consolidation of the health care industry to a new scale, Glaxo P.L.C. began an unsolicited $14 billion offer for Wellcome P.L.C. today, in a deal that would create the world's largest drug maker. If completed, the deal between the two British companies would be the largest in a string of ...

www.economist.com/node/112777

Feb 5, 1998 ... The marriage of Glaxo Wellcome and SmithKline Beecham will create the world's second-largest company. But size is no guarantee of success.

bciq.biocentury.com/companies/glaxo_wellcome_plc

Glaxo Wellcome's detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry analysis.

scrip.pharmaintelligence.informa.com/companies/198700516

Last October, PDI's LifeCycle Ventures Inc. subsidiary inked a five-year agreement with Glaxo Wellcome Inc. for the exclusive US marketing, sales, and distribution rights for Ceftin, an oral antibiotic used in treating acute bacterial respiratory infections. PDI had to create an infrastructure with all the various commercial ...